2002 History Law Safety 
NORML
AUGUST 29, 2019
In fact, it is precisely because marijuana use may pose potential risks to certain consumers — for example, adolescents or people with a family history of psychiatric illness — that NORML believes that lawmakers should regulate it accordingly. percent to 12.5
Cannabis Law Report
MAY 25, 2022
History – previous legal challenges relating to cannabis. Gareth Prince (Prince), one of the cited parties in the Cannabis judgment, is a practicing Rastafarian, and holder of a law degree, who resides in Cape Town. Subsequently, when Prince applied to the law society to be admitted as an attorney, they refused once again.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 9, 2021
The state of the law on psychedelic substances is in flux. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin. As such, the use, sale, and possession of psilocybin in the United States is illegal under federal law. have also passed “Right to Try” laws.
Cannabis Law Report
JANUARY 23, 2020
Given the law of 2 December 2016, n. 5; Given the law of 24 December 2012, no. 178/2002 of the European Parliament and of. Council of 28 January 2002, which establishes the principles and. general requirements of food law establishes. the European Food Safety Authority and establishes procedures in the.
Cannabis Law Report
MARCH 9, 2019
PUBLISHER: CANNABIS LAW REPORT. The law ((EU) 2015/2283), which applies across all member states, means any product deemed as ‘novel’ must gain authorisation from food authorities before it can be sold as a foodstuff within the EU. Jonathan Kirk QC specialises in consumer law and financial regulation. AUTHOR: Mark Taylor.
Cannabis Law Report
APRIL 8, 2022
To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. Rick Doblin, Ph.D., and Michael Mithoefer, M.D.,
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. It also has an extensive and diverse history of medicinal use. 2018 ; Frankhauser 2008 ). Bonini et al.
Expert insights. Personalized for you.
224 
Let's personalize your content